x

Posted 17 January, 2024

NeuBase Therapeutics, Inc. appointed Todd P. Branning as new CEO

Nasdaq:NBSE appointed new Chief Executive Officer Todd P. Branning in a 8-K filed on 17 January, 2024.


  On January 12, 2024, the Board of Directors (the "Board") of NeuBase Therapeutics, Inc. (the "Company") terminated the employment of Dietrich A. Stephan, Ph.D. as Chief Executive Officer of the Company, without cause, and appointed Todd P. Branning, who has served as the Company's Chief Financial Officer since January 2022, as the Company's interim Chief Executive Officer, in each case effective as of January 16, 2024.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of NeuBase Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.
Market Cap
$3.36M
View Company Details
NeuBase Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 12, 2024, the Board of Directors (the "Board") of NeuBase Therapeutics, Inc. (the "Company") terminated the employment of Dietrich A. Stephan, Ph.D. as Chief Executive Officer of the Company, without cause, and appointed Todd P. Branning, who has served as the Company's Chief Financial Officer since January 2022, as the Company's interim Chief Executive Officer, in each case effective as of January 16, 2024. Mr. Branning will continue in his role as the Company's Chief Financial Officer during his tenure as the Company's interim Chief Executive Officer. Dr. Stephan is expected to continue to serve on the Board.


Mr. Branning's compensation did not change as a result of this appointment. Biographical and additional information regarding Mr. Branning, including a discussion of Mr. Branning's offer letter and indemnification agreement with the Company, is contained in and incorporated herein by reference from the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 11, 2023. There are no family relationships between Mr. Branning and any director or executive officer of the Company, there are no arrangements or understandings with any other persons pursuant to which Mr. Branning was appointed as the Company's interim Chief Executive Officer, and there are no other transactions to which the Company is or was a participant and in which Mr. Branning has a material interest subject to disclosure under Item 404(a) of Regulation S-K.